In this fifth update to the living guidelines on drugs for the treatment of COVID-19, the World Health Organization analyzed results of clinical trials that assessed the effects of casirivimab-imdevimab and corticosteroids in patients with severe and non-severe disease.
BNT162b2 elicits relatively lower antibody levels to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor binding domain (RBD) than mRNA-1273, and lower antibody levels are observed with BNT162b2 in older versus younger adults.
Among patients with severe COVID-19 who were deemed not likely to benefit from invasive mechanical ventilation (nIMV), no difference in 30-day mortality was observed for those receiving continuous positive airway pressure (CPAP) or oxygen therapy.
In an assertive offensive against a resurgent COVID-19 pandemic, President Joe Biden announced sweeping new efforts at pressuring tens of millions of US government workers to get vaccinated against the illness or face disciplinary action.
For hospitalized adults with COVID-19, treatment with baricitinib in addition to standard of care does not reduce the frequency of disease progression overall, but it is associated with reduced mortality.
With the delta variant surging and many Americans mask- and vaccine-free, new cases of COVID-19 spiked to levels during the long Labor Day weekend that were 300 percent higher than those seen during the same weekend in 2020.